Prophase Labs (PRPH) Q4 2024 earnings summary

Executive summary

• Completed sale of Pharmaloz Manufacturing for $23 million, reducing debt and overhead, and focusing on high-value subsidiaries and potential liquidity events, including BE-Smart diagnostic, Nebula Genomics, and dietary supplements.

• Workforce reduced from 96 to 28 employees, with major cost reductions from shutting down Nebula Genomics Laboratory and cutting IT costs, improving margins and operational risk profile.

• Strategic initiatives include BE-Smart commercialization, Nebula Genomics restructuring, and a $50 million insurance recovery opportunity with Crown Medical Collections.

• Focus is now on building revenues and working towards profitability, with a leaner, more efficient structure.

• Several potential liquidity events are anticipated, including collections from COVID testing receivables, sale of Nebula Genomics, and a non-dilutive loan.

Financial highlights

• Sold Pharmaloz Manufacturing for $23 million, using proceeds to retire most company debt and clean up the balance sheet.

• Net revenue for 2024 was $6.8 million, down 80.6% from $35.0 million in 2023, mainly due to a sharp decline in COVID-19 diagnostic testing.

• Gross loss of $0.2 million in 2024 versus gross profit of $15.6 million in 2023; overall gross margin fell to (2.2)% from 44.5%.

• Net loss for 2024 was $53.4 million, or $(2.61) per share, compared to a net loss of $16.8 million, or $(0.98) per share, in 2023.

• Cash and cash equivalents at year-end 2024 were $0.7 million, with plans to secure a multi-million dollar loan to bridge to upcoming liquidity events.

Outlook and guidance

• BE-Smart diagnostic test to launch as a cash-pay product, targeting a $7–$14 billion annual U.S. market; peer-reviewed data publication expected within 2–4 months.

• Management expects the second quarter to show a dramatically improved cost structure and efficiency compared to previous quarters.

• $50 million potential insurance recovery could provide significant non-dilutive capital in the second half of 2025.

• No plans to invest heavily in new product commercialization; focus remains on partnerships and non-dilutive growth.

• Considering integrated telehealth and cross-sell initiatives leveraging existing infrastructure.